Levodopa/Carbidopa Fairmed (Levodopa, Carbidopa Monohydrate)

Levodopa serves as a biochemical precursor that crosses the blood‑brain barrier and is converted into dopamine by aromatic L‑amino acid decarboxylase within central neurons. The added dopamine compensates for the deficiency that characterises Parkinsonian disorders, thereby improving neurotransmission in motor pathways.

Dosing of Levodopa/Carbidopa Fairmed is individualized. The prescribing clinician determines the appropriate strength, frequency and titration schedule based on the patient’s disease stage, response, age and comorbid conditions. No fixed regimen is provided in public literature.

Safety data for Levodopa/Carbidopa in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is typically avoided unless clearly indicated by a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa/Carbidopa is considered the most effective symptomatic therapy for Parkinson’s disease, directly replenishing dopamine. Alternative classes such as dopamine agonists or MAO‑B inhibitors may be used as monotherapy or adjuncts, but they generally provide less robust motor control and have different side‑effect profiles.

Levodopa/Carbidopa Fairmed should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the container tightly closed and out of reach of children to maintain product stability.

The medication is taken orally, usually with a glass of water. It can be taken with or without food, although high‑protein meals may interfere with absorption. Tablets should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events include dyskinesia (involuntary movements), psychiatric disturbances such as hallucinations or psychosis, severe orthostatic hypotension leading to syncope, and rare cardiac arrhythmias. Patients should be monitored closely for these reactions, especially during dose adjustments.

The drug is contraindicated in individuals with known hypersensitivity to levodopa, carbidopa or any excipients, and in patients currently receiving non‑selective MAO inhibitors. Caution is also advised for those with narrow‑angle glaucoma, severe cardiovascular disease, or uncontrolled psychiatric disorders.